Vendor, Bethesda, MD
Abviro LLC
UEI K3L6KXJ9B6M7, CAGE 75YF3
2 awards and $9,318,257 obligated between February 14, 2024 and March 24, 2026, 100% under full and open competition, against 22.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $9,582,135 |
| Professional, Scientific, and Technical ServicesNAICS 541711 | -$263,878 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93023C00055Definitive Contract, February 14, 2024, Full and Open Competition, 31 offers | National Institutes of Health NiaidNational Institutes of Health | To Conduct a Phase 2 Dengue Human Challenge Clinical Trial of Abviro Anti-Dengue Monoclonal Antibody (Mab) AV-1.NAICS 541715, PSC AN12 | $9,582,135 |
| HHSN272201600028CDefinitive Contract, September 13, 2024, Full and Open Competition, 13 offers | National Institutes of Health NiaidNational Institutes of Health | The Purpose of This Contract Is to Develop a Monoclonal Antibody (Mab) AV-1 as a Safe Injectable Therapeutic.NAICS 541711, PSC AN12 | -$263,878 |
- Places of performance
- Maryland
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 8 across 2 awards